

TABLE OF CONTENTS

	Page
ACKNOWLEDGMENT	iii
ABSTRACT	iv
LIST OF TABLES	xii
LIST OF ILLUSTRATIONS	xiii
ABBREVIATIONS	xv
I. INTRODUCTION	1
II. LITERATURE REVIEWS	5
1. Overview of cancer	5
2. Colorectal cancer	5
2.1 Genetic alterations during the progression of colorectal cancer	6
2.2 Risk factors involved in colorectal cancer development	8
3. Liver cancer	9
3.1 Risk factors involved in liver cancer development	9
3.2 Liver cancer in Thailand	10
4. Lung cancer	11
4.1 Histologic types of lung cancer	11
4.2 Risk factors involved in lung cancer development	13
5. Staging of colorectal, liver, and lung cancer	14
6. Tumor markers currently used for diagnosis of cancer	18
6.1 Tumor markers for colorectal cancer	18

6.2 Tumor markers for liver cancer	19
6.3 Tumor markers for lung cancer	19
7. Cancer metastasis	20
8. Angiogenesis and angiogenic factors	21
9. Vascular endothelial growth factor (VEGF):	
The most studied angiogenic factor	23
10. The VEGF receptors	26
10.1 VEGFR-1	26
10.2 VEGFR-2	26
10.3 NEUROFILIN-1	27
10.4 VEGFR-3	27
11. Other VEGF-related genes	28
11.1 VEGF-B	28
11.2 VEGF-C	28
11.3 VEGF-D	29
11.4 VEGF-E	30
12. Regulation of VEGF gene expression	30
12.1 Oxygen tension	30
12.2 Hormones and cytokines	31
13. Expression pattern of VEGF in cancer	32
14. Diagnostic and prognostic value of circulating VEGF for malignant disease	32
III. MATERIALS AND METHODS	34
1. Specimen collection and storage	34
2. Preparation of tissue homogenate	34
3. Estimation of protein concentration in serum and tissue homogenate by the bicinchoninic acid (BCA) assay kit	35
3.1 Preparation of BSA (bovine serum albumin) standard	35

3.2	Preparation of BCA working reagent	36
3.3	Protein measurement by using microplate	36
4.	Assessment of tissue VEGF and circulating VEGF protein expression by Western blotting	36
4.1	Separation of protein by SDS-PAGE	37
4.1.1	Preparation of running gel (10% and 15%)	38
4.1.2	Preparation of stacking gel (4%)	38
4.1.3	Preparation of the sample and electrophoresis procedure	38
4.2	Transfer of separated proteins	39
4.3	Immunodetection	39
4.4	Visualization of detected protein band	40
4.5	Quantification of proteins on polyacrylamide gels by staining with coomassie blue	40
5.	Principle of Capture ELISA	41
5.1	Optimization of Capture ELISA	41
5.2	Capture ELISA procedure	44
5.3	Determination of the percentage of recovery of capture ELISA	45
6.	Statistical analysis	46
IV.	RESULTS	47
1.	Quality controls of the study	47
1.1	Controls for protein quantification	47
1.2	Control for protein loading	47
1.3	Control of VEGF protein	51
1.4	Control of total VEGF determination by ELISA	51
2.	Study population of the patients	53
3.	Expression pattern of VEGF isoform	54
3.1	Expression pattern of VEGF isoform in tumor tissue	54

3.2 Expression pattern of VEGF isoform in serum of cancer patients in comparison to serum of normal healthy volunteers	58
3.3 VEGF isoform expression in relation to classification of pathological features	58
4. Determination of total VEGF by ELISA	62
4.1 Optimization of the ELISA for the determination of total VEGF	62
4.2 Determination of specificity of the ELISA	65
4.3 Level of total VEGF protein in tumor tissues in comparison to normal tissues	66
4.4 Level of total VEGF protein in serum of cancer patients in comparison to healthy volunteers	66
V. DISCUSSION	68
VI. CONCLUSION	72
REFERENCES	73
APPENDICES	96
Appendix A: List of the chemicals and materials.	97
Appendix B: List of instruments.	99
Appendix C: Reagents and buffers preparation.	100
CURRICULUM VITAE	106

LIST OF TABLES

Table	Page
1 Staging system for colorectal cancer.	15
2 Staging system for liver cancer	16
3 Staging system for lung cancer	17
4 The preparations of serum sample for determination of the percentage of recovery	45
5 Clinical characteristics of the cancer patients	54
6 Summary of VEGF isoform expression in different types of tumor tissues	57
7 Summary of the relationship between VEGF isoform expression and pathological features in colorectal cancers	59
8 Summary of the relationship between VEGF isoform expression and pathological features in hepatocellular carcinoma	60
9 Summary of the relationship between VEGF isoform expression and pathological features in non-small cell lung cancers	61
10 The percentage of the recovery of standard VEGF from serum assessed by ELISA	65
11 Level of total VEGF protein in tumor tissues in comparison to normal tissues	66
12 Level of VEGF protein in serum of cancer patients in comparison to healthy volunteers	67

LIST OF ILLUSTRATIONS

Figure	Page
1 Genetic model for the progression of colorectal cancer.	6
2 Schematic diagram showing important domains different alternatively spliced variants of human VEGF.	25
3 Checkerboard of assay optimization utilize mouse anti-VEGF monoclonal Ab as a capture Ab and goat anti-VEGF polyclonal Ab as a detection Ab.	43
4 Checkerboard of assay optimization use goat anti-VEGF polyclonal Ab as a capture Ab and mouse anti-VEGF monoclonal Ab as a detection Ab.	44
5 An example of standard curve obtained from diluting BSA to various concentrations and detected by BCA protein assay.	48
6 The quality control chart of protein concentration of the control homogenate determined by BCA assay.	49
7 Western blots show unequality of β -actin protein and GAPDH protein in tumor and normal tissues.	50
8 An example of standard graph obtained from diluting recombinant VEGF to various concentrations and detected by ELISA assay.	52
9 The quality control chart of VEGF concentration of the control serum determined by Capture ELISA assay.	53
10a Protein expression VEGF isoform in patients with colorectal cancer assessed by Western blotting in tumor tissues and corresponding adjacent normal tissues	55

Figure	Page
10b Protein expression VEGF isoform in patients with liver cancer assessed by Western blotting in tumor tissues and corresponding adjacent normal tissues.	56
10c Protein expression VEGF isoform in patients with lung cancer assessed by Western blotting in tumor tissues and corresponding adjacent normal tissues.	57
11 Western blot analysis of VEGF in serum from cancer patient compare to normal serum.	58
12 Optimization of capture ELISA using mouse anti-monoclonal Ab as capture Ab and goat anti-polyclonal Ab as detection Ab	63
13 Optimization of capture ELISA using goat anti-polyclonal Ab as capture Ab and mouse anti-monoclonal Ab as detection Ab	64

ABBREVIATIONS

%	percentage
°C	degree celsius
α	alpha
μg	microgram
APS	Ammonium persulfate
BCA	bicinchoninic acid
β	beta
BSA	bovine serum albumin
cm	centimetre
CV	coefficient of variation
ddH ₂ O	deionized water
dH ₂ O	distilled water
DNA	deoxyribonucleic acid
ECL	enhanced chemiluminescence
ELISA	Enzyme-linked immunosorbent assay
gm	gram
HCl	hydrochloric acid
hr	hour
HRP	horseradish peroxidase
H ₂ SO ₄	sulfuric acid
IgG	immunoglobulin G
Kb	kilobase pair
kDa	kilodalton
KCl	potassium chloride

KH_2PO_4	potassium dihydrogen phosphate
M	molar
mg	milligram
min	minute
ml	millilitre
mRNA	messenger ribonucleic acid
ng	nanogram
nm	nanometre
Na_2HPO_4	di-sodium hydrogen phosphate
OCV	optimal condition variance
PBS	phosphate buffer saline
PBS-T	phosphate buffer saline-Tween
pg	picrogram
R	recovery
RCV-K	routine condition variances known values
RT	room temperature
SD	standard deviation
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TMB	3,3,5,5 tetramethylbenzidine
TMED	<i>N, N, N', N'</i> -tetramethylethylenediamine
VEGF	Vascular endothelial growth factor